WCM Investment Management LLC Grows Position in Charles River Laboratories International, Inc. (NYSE:CRL)

WCM Investment Management LLC grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 33.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,367 shares of the medical research company's stock after acquiring an additional 2,589 shares during the quarter. WCM Investment Management LLC's holdings in Charles River Laboratories International were worth $2,056,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Boston Trust Walden Corp raised its stake in Charles River Laboratories International by 2.8% in the 2nd quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company's stock worth $41,381,000 after acquiring an additional 5,375 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Charles River Laboratories International by 5.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company's stock valued at $15,401,000 after acquiring an additional 2,739 shares during the last quarter. Natixis acquired a new position in shares of Charles River Laboratories International in the 1st quarter worth $1,058,000. Tidal Investments LLC increased its position in Charles River Laboratories International by 99.8% in the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company's stock worth $1,435,000 after buying an additional 2,646 shares during the period. Finally, Epoch Investment Partners Inc. grew its stake in shares of Charles River Laboratories International by 2,733.4% during the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company's stock valued at $67,060,000 after purchasing an additional 238,766 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 2.2 %

Shares of NYSE:CRL traded down $4.85 during midday trading on Tuesday, reaching $215.84. The company had a trading volume of 756,423 shares, compared to its average volume of 617,355. The stock has a market capitalization of $11.04 billion, a P/E ratio of 27.62, a PEG ratio of 5.80 and a beta of 1.38. Charles River Laboratories International, Inc. has a one year low of $168.24 and a one year high of $275.00. The stock's fifty day moving average price is $194.37 and its 200-day moving average price is $208.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.21.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.72 earnings per share. Equities research analysts expect that Charles River Laboratories International, Inc. will post 10.2 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has approved a stock buyback program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

CRL has been the topic of several recent research reports. CLSA raised Charles River Laboratories International from an "underperform" rating to a "hold" rating and set a $205.00 price objective on the stock in a report on Thursday, November 7th. Barclays lowered their price target on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating on the stock in a report on Thursday, August 8th. StockNews.com cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Baird R W cut Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 8th. Finally, Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a "sell" rating and a $151.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and an average price target of $217.54.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).